GREY:VPHIF - Post by User
Comment by
eric40on Dec 10, 2020 8:01pm
191 Views
Post# 32085400
RE:RE:Rock and Roll
RE:RE:Rock and Roll Redeska approval is big awaited news that will a a dramatic impact on 2021 and future revenu. As a generic heparin, the only one available, provinces where it is mandatory to buy generic first if available will have to bur Valeo's generic heparine (Redeska). And I bet that with covid impact on province's deficit, the rest of the provinces where it is not madatory yet will make it madatory soon enough to buy generic first so the 200 millions heparin market should shift largely to generic so Valeo sales projections for Redeska will probably be 2X to 6 X mid term IMHO.
I believe the short sales will be much higher on the next report mid december as short seller had a good opportunity with the tax loss season to sell the news
People who bought higher than 1.40$ to 1.50$ might want to take a loss.
If I am right, the january effect should be quite good for Valeo IMO once the last trading days of 2020 will be done and shorts will have cover.
We will see if that make sense on the next short report on december 16 unless shorts covert by then (a short short sale!)
Anyway, I am bullish more than ever now with Redeska approval.
GLTA